Sichenzia Ross Ference LLP Represents ThinkEquity in $2.0 Million Underwritten Public Offering of ADSs of Immuron Limited.
Press Release – New York, NY – May 29, 2019 – Sichenzia Ross Ference LLP announced today that it has represented ThinkEquity, a Division of Fordham Financial Management, Inc. as sole book runner in a $2.0 million Public Offering of American Depositary Shares (ADSs) of Immuron Limited (ASX: “IMC”; NASDAQ “IMRN”).
The offering consisted of 500,000 ADS’s at a price of $4.00 per ADS for gross proceeds to the Company of $2.0 million. Immuron is an Australian biopharmaceutical company focused on oral immunoglobulin therapeutics. The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia and Tara Guarneri-Ferrara and included Jeff Cahlon and Jacob Tabman.
.jpg)
Sichenzia Ross Ference LLP
Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.
Visit SRF's LinkedIn page
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019
